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BACKGROUND. Few studies have examined the outcomes for Hispanic men with
prostate carcinoma and incorporated socioeconomic factors in association with
race/ethnicity in affecting survival, adjusting for factors on cancer stage, grade,
comorbidity, and treatment.
METHODS. We studied a population-based cohort of 61,228 men diagnosed with
local or regional stage prostate carcinoma at age 65 years or older between 1992
and 1999 in the 11 SEER (Surveillance, Epidemiology, and End Results) areas,
identified from the SEER-Medicare linked data with up to 11 years of followup.
RESULTS. Low socioeconomic status was significantly associated with decreasing
survival in all men with prostate carcinoma. Those living in the community with
the lowest quartile of socioeconomic status were 31% more likely to die than those
living in the highest quartile (hazard ratio [HR] of all-cause mortality: 1.31; 95%
confidence interval [CI]: 1.25–1.36) after adjustment for patient age, comorbidity,
Gleason score, and treatment. The HR remained almost unchanged after control-
ling for race/ethnicity (HR: 1.32; 95% CI: 1.26–1.38). Compared with Caucasians,
the risk of mortality in African American men was marginally significantly higher
(HR: 1.06; 95% CI: 1.01–1.11) after controlling for education, and no longer signif-
icant after adjusting for poverty, income, or composite socioeconomic variable; the
HR was lower for Hispanic men (HR: 0.80; 95% CI: 0.72–0.89) after adjustment for
education and other socioeconomic variables.
CONCLUSION. Racial disparity in survival among men with local or regional prostate
carcinoma was largely explained by socioeconomic status and other factors. Lower
socioeconomic status appeared to be one of the major barriers to achieving
comparable outcomes for men with prostate carcinoma. Cancer 2006;106:
1276–85. © 2006 American Cancer Society.
KEYWORDS: prostate carcinoma, race/ethnicity, disparity, socioeconomic status,
survival.
There are remarkable worldwide variations in the incidence ofprostate carcinoma, with the highest age-standardized incidence
rate in the US.1 In the US, prostate carcinoma is currently the most
commonly diagnosed cancer in men, and incidence and mortality
varies greatly by race/ethnicity.2–6 Previous studies have shown that
the increased mortality in African American patients with prostate
carcinoma can be attributed to more aggressive cancers and more
advanced stage-at-diagnosis,7–9 differences in treatment,10–19 socio-
economic factors,20–23 and physician characteristics.24 For example,
results from the Prostate Cancer Outcomes Study demonstrated that
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African Americans with more aggressive prostate car-
cinoma were less likely to undergo radical prostatec-
tomy and more likely to be treated conservatively than
Caucasians.13 However, few studies have examined
the outcomes in Hispanic men and incorporated so-
cioeconomic factors in association with race/ethnicity
and determined their impact on the survival of men
with prostate carcinoma, in addition to factors on
cancer stage, grade, comorbidity, and treatment. A
large cohort of men diagnosed with local/regional
stage prostate carcinoma at age 65 or older, identified
from the nationwide, population-based Surveillance,
Epidemiology, and End Results (SEER) cancer regis-
tries–Medicare linked databases with up to 11 years of
followup, were studied to examine the effect of race/
ethnicity and socioeconomic factors on long-term sur-
vival. These linked data not only provided accurate
information on tumor stage and grade (Gleason score)
at diagnosis and long-term followup of the vital status,
but also allowed the examination of various socioeco-
nomic factors at the level of census tract and zip
codes. In addition, comorbid conditions and the type
of treatment (chemotherapy and hormonal therapy)
could be uniquely identified from Medicare claims
data. We hypothesized that there were no racial and
ethnic differences in long-term survival of prostate
carcinoma patients after controlling for differences in
age, tumor Gleason score, comorbidity, treatment,
and socioeconomic status.
MATERIALS AND METHODS
Data Sources
The SEER program, supported by the National Cancer
Institute (NCI), includes population-based tumor reg-
istries in 11 selected geographic areas3,4,25,26: the met-
ropolitan areas of San Francisco/Oakland, Detroit, At-
lanta, and Seattle; Los Angeles county; the San Jose–
Monterey area; and the states of Connecticut, Iowa,
New Mexico, Utah, and Hawaii, covering  14% of the
US population. The registries ascertain all newly diag-
nosed (incident) prostate carcinoma cases from mul-
tiple reporting sources such as hospitals, outpatient
clinics, and laboratories.
The Medicare program provides payments for
hospital, physician, and outpatient medical services
for  97% of persons age  65.27,28 Cases reported by
the SEER cancer registries from 1973–1999 were
matched against the Medicare master enrollment files.
Medicare claims data are available through 2002. For
persons age  65 appearing in the SEER records,
Medicare eligibility could be identified for 94% of
these cases. The method of linking these data has been
described elsewhere.25,26 The Committee for Protec-
tion of Human Subjects at the University of Texas
Health Science Center at Houston approved this
study.
Study Population
Our study is based on the analytical SEER-Medicare
files that excluded men who did not have full coverage
of both Medicare Parts A and B, and were members of
Health Maintenance Organizations (HMOs) to ensure
the completeness of Medicare claims. The study pop-
ulation consisted of 61,228 men diagnosed with local/
regional stage prostate carcinoma at age 65 between
1992 and 1999 from the 11 SEER areas. Because local
and regional diseases were combined as a single cat-
egory in SEER data, we were unable to further stratify
the analysis by local versus regional stage. However,
we used the American Joint Committee on Cancer
(AJCC) stage available in SEER to control for residual
confounding, although 37% of cases had missing in-
formation. Of the 61,228 men, 53,764 were Caucasians
(non-Hispanic whites), 6,321 African Americans (non-
Hispanic blacks), and 1,143 Hispanics.
Study Variables
Outcome variables
The survival time in months was calculated from the
date of diagnosis to the date of death or to the date of
last followup (December 31, 2002). Because SEER re-
ported only the month and year of diagnosis, we ar-
bitrarily defined the day of diagnosis as the 15th of the
month. All-cause mortality was defined as death from
any cause that was the underlying cause of death,
which was identified by the SEER program through
linking the SEER data with the National Death Index
data from the National Center for Health Statistics.
Patients still alive at the last followup were censored.
Prostate carcinoma-specific mortality was defined as
prostate carcinoma as the underlying cause of death.
In this specific analysis, patients who died of causes
other than prostate carcinoma or were still alive at the
last followup were censored.
Socioeconomic status
Three variables from the 1990 census available in the
SEER-Medicare linked data were used to define socio-
economic status: 1) education: percent of adults age
 25 who had younger than 12 years of education at
the zip code level, which was categorized into quar-
tiles: first ( 11.9%), second (11.9–18.1%), third (18.2–
26.2%), and fourth quartile ( 26.2%); 2) poverty:
percent of persons living below the poverty line at
the census tract level, which was categorized into
quartiles: first ( 3.6%), second (3.6–6.7%), third (6.8–
12.6%), and fourth quartile ( 12.6%); 3) income:
median annual household income at the zip code
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level, which was also categorized into quartiles: first
( $43,875), second ($34,807–43,875), third ($26,111–
34,806), and fourth quartile ( $26,111). We used pov-
erty at the census tract level because this variable is
not available at the zip code level. For elderly Medi-
care beneficiaries, poverty level could be the most
directly relevant proxy measure of their economic sta-
tus.27
In addition to these socioeconomic variables, we
also created a composite variable that was generated
by combining these three variables based on the
methods of Robert et al.28
The above three socioeconomic variables were
first recoded to ensure that lower values represent
higher socioeconomic status (income was made neg-
ative). We then converted these values into normal
scores. Finally, we summed the scores of these three
variables that were equally weighted and categorized
the total scores into quartiles. Those subjects with
missing information on socioeconomic status were
categorized separately.
Comorbidity index
Comorbidity was ascertained fromMedicare claims by
identifying diagnoses or procedures performed be-
tween 1 year before and 1 month after the diagnosis of
prostate carcinoma. Details on creating a comorbidity
score have been previously reported.29,30
Treatment
Surgery and radiation therapy
Patients were defined as having received radical pros-
tatectomy if it was indicated in the SEER data (codes
40–70)31 or if there was a Medicare claim for radical
prostatectomy (ICD-9 code32 of 605, or CPT codes33 of
55810–55815 or 55840–55845). Patients were defined
as having received radiation therapy if either SEER or
Medicare claims so indicated.34
Hormonal therapy
Patients with prostate carcinoma were defined as hav-
ing received hormonal therapy (androgen deprivation
therapy) if any of the following Medicare procedure
codes indicated so within 6 months of the diagno-
sis33,35: the procedure codes for leuprolide (J1950 or
J9217–J9219) and for goserelin (J9202); or procedure
codes for orchiectomy (54520–54521, 54530, or 54535).
Chemotherapy
The detailed methods for the identification of chemo-
therapy use through Medicare claims have been pre-
viously described.36 In brief, patients with prostate
carcinoma were defined as having received chemo-
therapy if any of the following Medicare procedure
codes so indicated within 6 months of diagnosis31–36:
the ICD-9-CM procedure code of 99.25 and V codes of
V58.1, V66.2, or V67.2; the procedure codes of 96400–
96549, J8530–J8999, J9000–J9999 (except those codes
for hormonal therapy), Q0083–Q0085; or revenue cen-
ter codes of 0331, 0332, and 0335.
Other Characteristics
Patient and tumor characteristics such as age at diag-
nosis (categorized as 65–69, 70–74, 75–79, 80 or older),
race/ethnicity (Caucasian, African American, and His-
panic), AJCC stage (I, II, III, IV, or unknown), grade
(Gleason score), year of diagnosis (1992–1999), and
geographic area (11 SEER areas) were available from
SEER.
Analysis
The differences in the distribution of baseline charac-
teristics among the three racial/ethnic groups were
tested using the chi-square statistic. The Cox propor-
tional hazard regression model was used for analysis
of survival using the PHREG procedure in the SAS
system (Cary, NC).37 The proportionality assumption
was satisfied when the log–log Kaplan–Meier curves
for survival functions by race/ethnicity or socioeco-
nomic status were parallel and did not intersect.37,38
The interaction between race/ethnicity and socioeco-
nomic status was tested using the product term of
these two variables in the model. Analyses were ad-
justed for age, tumor AJCC stage, Gleason score, treat-
ment (surgery or radiation, chemotherapy, or hor-
monal therapy), comorbidity score, year of diagnosis,
and geographic area. A series of statistical models
were tested for the associations between survival and
socioeconomic status and race/ethnicity and are also
noted in the table footnotes.
RESULTS
Table 1 presents the distribution of patient age, tumor
characteristics, and type of treatment among three
racial/ethnic groups of patients diagnosed with local/
regional stage prostate carcinoma. A higher propor-
tion of cases were diagnosed at age  80 in Caucasian
men (16.3%) than in African Americans (13.5%),
whereas Hispanics had the highest percentage (36.0%)
of cases diagnosed at age 65–69. A slightly greater
proportion of cases were diagnosed at a lower tumor
grade or lower Gleason score and had a lower comor-
bidity score in Caucasian and Hispanic men than that
in African Americans. Although significant, the per-
centage of men receiving various treatments was rel-
atively close among ethnic groups. For example, 23.9%
of African Americans received hormonal therapy com-
pared with 27.0% of Caucasians and 28.7% of Hispan-
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ics. Similarly, 42.7% of African Americans received
neither radical prostatectomy nor radiation compared
with 35.6% of Caucasians and 40.4% of Hispanics.
Table 2 presents the distribution of socioeco-
nomic status among three racial/ethnic groups of pa-
tients. A large proportion of African American and
Hispanic men were in the poorest quartiles of educa-
tion, poverty, income, and composite socioeconomic
status compared with that of Caucasians. For example,
73.4% of African Americans and 60.6% of Hispanics
were in the poorest quartile of socioeconomic status
as measured by the poverty level compared with
17.9% of Caucasians. The differences in the distribu-
tion of the above factors in Tables 1 and 2 between
Caucasians and African Americans or Hispanics were
all statistically significant.
Table 3 presents the 3-, 5-, and 10-year survival by
racial/ethnic groups and socioeconomic status. Be-
cause the last date of followup in Medicare was De-
cember 2002, all cases in our study cohort had been
followed for at least 3 years. The 3-year survival from
all-causes was 91% in Hispanics, 87.8% in Caucasians,
and 84.1% in African Americans. Survival increased
with improving socioeconomic status. For example,
the 3-year survival was 84.5% in subjects who lived in
the community with lowest education level, and 90.6%
in those with highest quartile of education. The im-
provement in survival associated with higher socio-
economic status was consistent when using other
measures of socioeconomic status (poverty, income,
and composite socioeconomic status). This survival
pattern in association with race/ethnicity and socio-
economic status was similar at the 5- and 10-year level
and for prostate carcinoma specific survival (Table 3).
Table 4 presents the effect of socioeconomic fac-
tors on all-cause mortality and prostate carcinoma-
TABLE 1
Comparison of Demographic and Tumor Characteristics and Type of
Treatment among Different Racial or Ethnic Groups in Men with
Locoregional Prostate Carcinoma
Characteristic
Caucasian
African
American Hispanic
n % n % n %
Median age, yrs (range) 73 (65–103) 72 (65–103) 71 (65–101)
Age, yrs
65–69 15,416 28.7 2131 33.7 411 36.0
70–74 17,324 32.2 2023 32.0 390 34.1
75–79 12,271 22.8 1314 20.8 221 19.3
 80 8753 16.3 853 13.5 121 10.6
AJCC stage
I 17,636 32.8 2263 35.8 387 33.9
II 6701 12.5 866 13.7 147 12.9
III 7717 14.4 681 10.8 173 15.1
IV 1733 3.2 212 3.4 48 4.2
Unknown 19,977 37.2 2299 36.4 388 34.0
Gleason score
2–4 7475 13.9 740 11.7 198 17.3
5–7 33,218 61.8 3789 59.9 650 56.9
8–10 10,438 19.4 1410 22.3 240 21.0
Unknown 2633 4.9 382 6.0 55 4.8
Comorbidity score
0 34,402 64.0 3394 53.7 669 58.5
1 12,565 23.4 1611 25.5 290 25.4
2 4342 8.1 747 11.8 96 8.4
 3 2455 4.6 569 9.0 88 7.7
Surgery and radiation
Radical prostatectomy 12,907 24.0 1070 16.9 328 28.7
Radiation 20,536 38.2 2463 39.0 327 28.6
Both 1205 2.2 89 1.4 26 2.3
Neither 19,116 35.6 2699 42.7 462 40.4
Chemotherapy
None 44,219 82.3 5345 84.6 861 75.3
Yes 9545 17.8 976 15.4 282 24.7
Hormonal therapy
None 39,266 73.0 4808 76.1 815 71.3
Yes 14,498 27.0 1513 23.9 328 28.7
Total 53,764 100.0 6321 100.0 1143 100.0
AJCC: American Joint Commission on Cancer.
TABLE 2
Comparison of SES among Different Racial or Ethnic Groups in Men
with Prostate Carcinoma
SES
(quartile from high to
low)
Caucasian
African
American Hispanic
n % n % n %
Education
1st 14,437 26.9 237 3.8 60 5.3
2nd 14,059 26.2 472 7.5 122 10.7
3rd 13,034 24.2 1168 18.5 225 19.7
4th 9193 17.1 4260 67.4 666 58.3
Missing 3041 5.7 184 2.9 70 6.1
Poverty
1st 14,861 27.6 267 4.2 69 6.0
2nd 14,429 26.8 529 8.4 132 11.6
3rd 13,974 26.0 838 13.3 208 18.2
4th 9603 17.9 4639 73.4 693 60.6
Missing 897 1.7 48 0.8 41 3.6
Income
1st 14,033 26.1 288 4.6 99 8.7
2nd 13,593 25.3 587 9.3 175 15.3
3rd 12,772 23.8 1438 22.8 322 28.2
4th 10,325 19.2 3824 60.5 477 41.7
Missing 3041 5.7 184 2.9 70 6.1
Composite SES
1st 14,059 26.2 204 3.2 56 4.9
2nd 13,732 25.5 460 7.3 121 10.6
3rd 13,199 24.6 914 14.5 199 17.4
4th 9128 17.0 4528 71.6 661 57.8
Missing 3646 6.8 215 3.4 106 9.3
Total 53,764 100.0 6321 100.0 1143 100.0
SES: socioeconomic status.
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specific mortality while adjusting for race/ethnicity
and other factors. There was a clear pattern for the
increasing hazard ratio (HR) of mortality associated
with lower socioeconomic status. The magnitude and
trend in HRs were consistent regardless of which so-
cioeconomic variables were used. For example, those
living in communities with the lowest composite so-
cioeconomic level were 31% more likely to die from
all-causes than those living in the highest socioeco-
nomic level communities (P  0.001 for trend) (Model
1). The risk of all-cause mortality remained almost
unchanged after controlling for race/ethnicity (Model
2). Whereas the HR for prostate carcinoma-specific
mortality was reduced slightly after adjusting for race/
ethnicity, those living in communities with the lowest
socioeconomic status were still considerably more
likely to die than those living in communities with the
highest quartile (Model 4).
The effects of race/ethnicity on the risk for all-
cause mortality and prostate carcinoma-specific mor-
tality are presented in four different statistical models
in Table 5. Compared with Caucasian men, African
Americans were 14% more likely to die and Hispanic
men were 15% less likely to die, after controlling for
other factors. When additionally controlled for com-
posite socioeconomic status, the HR of all-cause mor-
tality was no longer significantly higher in African
Americans compared with Caucasians (HR: 1.01; 95%
confidence interval [CI]: 0.96–1.06), whereas Hispanic
men were still significantly less likely to die than Cau-
casians (HR: 0.78; 95% CI: 0.70–0.87). When con-
trolled for poverty or median income, there was no
significant difference in all-cause mortality between
Caucasian and African American men. For example,
when controlled for income, the HR in African Amer-
icans was no longer significantly higher (HR: 1.02; 95%
CI: 0.98–1.08) compared with Caucasians, whereas
Hispanics still had a significantly lower risk (HR: 0.79;
95% CI: 0.71–0.88). Similarly, after adjusting for pov-
erty, the HR was 1.04 (95% CI: 0.99–1.09) for African
Americans and 0.80 (95% CI: 0.72–0.89) for Hispanics
as compared with Caucasians. However, the HR was
substantially reduced but still marginally higher in
African American men after adjusting for education
(HR: 1.06; 95% CI: 1.01–1.11), whereas Hispanic men
were significantly less likely to die than Caucasians
(HR: 0.80; 95% CI: 0.72–0.89).
African American patients also had a higher but
insignificant risk of prostate carcinoma-specific mor-
tality than Caucasians, whereas Hispanics had a lower
but insignificant risk of prostate carcinoma-specific
mortality after adjusting for composite socioeconomic
status in addition to other factors (Model 4). However,
the HRs of prostate carcinoma-specific mortality were
significantly higher in African Americans after adjust-
ing for education (HR: 1.20; 95% CI: 1.03–1.39), in-
come (HR: 1.18; 95% CI: 1.01–1.38), or poverty (HR:
1.19; 95% CI: 1.02–1.40), and were not significantly
lower in Hispanics (HR: 0.79; 95% CI: 0.53–1.16; 0.80;
95% CI: 0.54–1.18; and 0.80; 95% CI: 0.54–1.18, respec-
tively) as compared with Caucasians.
Figure 1 presents the Kaplan–Meier survival curve
for three racial/ethnic groups and the number of cases
at risk. It was clear that the survival was the lowest for
African American patients and the highest for His-
panic, whereas the survival curve for Caucasian pa-
tients was between African Americans and Hispanics.
Table 5 also presents the effect of age, Gleason
score, and comorbidity on mortality. The HR of all-
cause and prostate carcinoma-specific mortality in-
TABLE 3
Survival in Men with Locoregional Prostate Carcinoma by Race or
Ethnicity and SES
Race or ethnicity and SES
(quartile from high to low)
3-yr survival (%)
(cases in 1992-
1999)
5-yr survival (%)
(cases in 1992-
1997)
10-yr survival
(%) (cases in
1992–1993)
All
causes
Disease-
specific
All
causes
Disease-
specific
All
causes
Disease-
specific
Racial or ethnic group
Caucasian 87.8 98.2 78.0 96.4 52.6 94.0
African American 84.1 97.5 72.6 95.3 43.3 91.1
Hispanic 91.0 98.9 83.5 97.3 61.3 95.6
Education
1st 90.6 98.7 82.6 97.3 59.5 95.4
2nd 88.2 98.3 78.9 96.6 53.0 93.9
3rd 86.3 98.0 75.6 95.9 49.5 93.0
4th 84.5 97.6 72.9 95.4 45.2 92.3
Missing 87.7 98.7 77.0 97.1 54.1 94.6
Poverty
1st 89.9 98.4 81.3 96.8 56.4 94.6
2nd 88.3 98.2 79.2 96.4 54.2 93.9
3rd 87.6 98.4 77.3 96.6 51.7 94.2
4th 84.1 97.7 72.3 95.5 41.8 92.2
Missing 87.1 98.6 77.2 96.2 54.6 91.6
Income
1st 90.0 98.5 81.6 97.0 56.9 94.5
2nd 88.0 98.1 79.0 96.4 53.5 94.1
3rd 86.9 98.2 76.4 96.6 51.0 94.0
4th 84.8 97.7 73.1 95.5 45.7 92.1
Missing 87.7 98.7 77.0 96.2 54.1 94.6
Composite SES
1st 90.6 98.7 82.5 97.2 58.6 94.9
2nd 88.3 98.1 79.1 96.3 53.9 93.9
3rd 86.9 98.3 76.4 96.3 50.5 94.0
4th 84.0 97.5 72.1 95.4 44.1 92.0
Missing 87.5 98.7 77.1 96.9 54.1 94.1
Total 87.5 98.2 77.5 96.3 51.9 93.7
SES: socioeconomic status.
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creased significantly with age (P  0.001). The HR also
increased with more advanced tumor stage, poorer
grades, and higher comorbidity scores, but the mag-
nitude of the increased risk was much greater for
prostate carcinoma-specific mortality in association
with Gleason score and AJCC stage, whereas the mag-
nitude of the risk was greater for all-cause mortality in
association with comorbidity.
There was no significant interaction between
race/ethnicity and socioeconomic status (education,
income, poverty, and composite socioeconomic sta-
tus) on the risk of mortality. For example, in every
quartile of educational level there was no significant
difference in HR of both all-cause and prostate carci-
noma-specific mortality between African American
and Caucasian men, whereas Hispanic men were sig-
nificantly less likely to die of all causes in the second
and fourth quartiles, but had no significantly different
risk of prostate carcinoma-specific mortality com-
pared with Caucasians.
DISCUSSION
This study examined the disparities in race/ethnicity
and socioeconomic factors in association with survival
among men diagnosed with prostate carcinoma. We
found that in men with local or regional stage prostate
carcinoma, lower socioeconomic status was signifi-
cantly associated with decreased survival, even after
controlling for other patient/tumor characteristics
and treatment. We also found racial/ethnic disparities
in survival, but these disparities reduced substantially
after controlling for socioeconomic factors. Particu-
larly when poverty or income or composite variables
were used as indicators of socioeconomic status, the
risk of all-cause mortality in African American patients
was no longer significantly higher than that in Cauca-
sians, indicating that racial/ethnic differences in sur-
vival for prostate carcinoma between African Ameri-
can and Caucasian men were largely explained by
socioeconomic status and other factors.
The differences in survival between African
TABLE 4
Association between Mortality and SES in Men with Prostate Cancer in 1992–1999
SES
(quartile from
high to low)
Hazard ratio (95% CI) of mortalitya
All-cause mortality Prostate cancer-specific mortality
Model 1 Model 2 Model 3 Model 4
Education
1st 1.0 1.0 1.0 1.0
2nd 1.12 (1.08–1.17) 1.12 (1.08–1.17) 1.15 (1.00–1.33) 1.13 (0.98–1.30)
3rd 1.18 (1.14–1.23) 1.18 (1.13–1.23) 1.28 (1.11–1.48) 1.27 (1.11–1.47)
4th 1.27 (1.22–1.32) 1.26 (1.20–1.31) 1.43 (1.25–1.65) 1.39 (1.20–1.61)
Missing 1.19 (1.11–1.27) 1.19 (1.11–1.27) 1.02 (0.79–1.31) 0.98 (0.76–1.26)
Poverty
1st 1.0 1.0 1.0 1.0
2nd 1.11 (1.06–1.15) 1.11 (1.06–1.15) 1.17 (1.02–1.33) 1.15 (1.01–1.32)
3rd 1.19 (1.14–1.24) 1.19 (1.14–1.24) 1.12 (0.97–1.30) 1.11 (0.96–1.28)
4th 1.28 (1.23–1.34) 1.28 (1.22–1.34) 1.36 (1.18–1.55) 1.31 (1.13–1.52)
Missing 1.14 (1.02–1.28) 1.14 (1.02–1.28) 1.60 (1.10–2.32) 1.49 (1.03–2.16)
Income
1st 1.0 1.0 1.0 1.0
2nd 1.12 (1.08–1.17) 1.12 (1.08–1.17) 1.17 (1.02–1.34) 1.16 (1.01–1.33)
3rd 1.22 (1.17–1.28) 1.22 (1.17–1.28) 1.28 (1.11–1.48) 1.25 (1.08–1.45)
4th 1.28 (1.23–1.34) 1.28 (1.22–1.34) 1.43 (1.23–1.67) 1.37 (1.16–1.61)
Missing 1.21 (1.13–1.30) 1.21 (1.13–1.29) 1.02 (0.79–1.32) 0.98 (0.76–1.27)
Composite SES
1st 1.0 1.0 1.0 1.0
2nd 1.11 (1.07–1.16) 1.11 (1.07–1.16) 1.26 (1.09–1.44) 1.25 (1.09–1.44)
3rd 1.22 (1.17–1.27) 1.22 (1.17–1.27) 1.24 (1.07–1.43) 1.22 (1.05–1.41)
4th 1.31 (1.25–1.36) 1.31 (1.25–1.37) 1.48 (1.28–1.70) 1.40 (1.20–1.64)
Missing 1.19 (1.11–1.26) 1.19 (1.12–1.26) 1.13 (0.89–1.34) 1.11 (0.88–1.40)
SES: socioeconomic status; 95% CI: 95% confidence interval; AJCC: American Joint Commission on Cancer; SEER: Surveillance, Epidemiology, and End Results.
a In models 1 and 3, the hazard ratio is adjusted for age, comorbidity, AJCC stage, Gleason score, year of diagnosis, SEER region, surgery and radiation, hormone, and chemotherapy. Models 2 and 4 are adjusted
for race or ethnicity, in addition to factors in Models 1 and 3.
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American and Caucasian patients have been attrib-
uted to numerous factors.7–24 A recent study re-
ported that African American patients may be more
likely to seek physicians who provide poorer quality
of care.24 Although racial/ethnic differences are
likely multifactorial, access to quality care and so-
cioeconomic factors are shown to play a major
role.10–24 Several studies demonstrated that if pa-
tients had equal access to quality healthcare, the
outcomes would be similar among different racial
groups.10,15,39 However, other studies showed the
racial disparities still existed even after controlling
for socioeconomic factors and for access to equita-
ble care and treatment.18,22 Our study showed that
among patients who had the same coverage of
Medicare insurance and had same stage (local/re-
gional) prostate carcinoma, African American men
were more likely to present with a higher-grade
cancer. Although the receipt of treatment differed
among racial/ethnic groups, the impact of this fac-
tor was minimal in this cohort of cases. However,
differences in mortality between African American
and Caucasian men were substantially reduced (af-
ter adjusting for education) or no longer existed
(after adjusting for poverty or income or composite
socioeconomic variable). This indicates that socio-
economic differences are one of the major barriers
to achieving equal outcomes for men with prostate
carcinoma. These socioeconomic differences are
modifiable factors that have important implications
in our society. If we make efforts to achieve equal
opportunity for education, employment, and health
TABLE 5
Mortality Associated with Race or Ethnicity and SES in Men with Locoregional Prostate Carcinoma
Race or ethnicity and other factors
Hazard ratio (95% CI) of mortalitya
All-cause mortality Prostate cancer-specific mortality
Model 1 Model 2 Model 3 Model 4
Race or ethnicity
Caucasian 1.00 1.00 1.00 1.00
African American 1.14 (1.09–1.19) 1.01 (0.97–1.06) 1.33 (1.16–1.53) 1.17 (0.99–1.37)
Hispanic 0.85 (0.76–0.94) 0.78 (0.70–0.87) 0.84 (0.57–1.24) 0.78 (0.53–1.16)
Age, yrs
65–69 1.0 1.0 1.0 1.0
70–74 1.24 (1.19–1.29) 1.24 (1.19–1.29) 1.17 (1.02–1.35) 1.17 (1.01–1.34)
75–79 1.73 (1.66–1.81) 1.73 (1.66–1.81) 1.44 (1.25–1.67) 1.45 (1.25–1.67)
 80 3.01 (2.88–3.15) 2.99 (2.86–3.13) 2.41 (2.08–2.79) 2.39 (2.07–2.77)
AJCC stage
I 1.0 1.0 1.0 1.0
II 1.13 (1.08–1.18) 1.13 (1.08–1.18) 1.40 (1.19–1.64) 1.39 (1.18–1.64)
III 1.21 (1.16–1.27) 1.21 (1.15–1.27) 1.93 (1.66–2.24) 1.92 (1.65–2.23)
IV 1.67 (1.56–1.79) 1.66 (1.55–1.78) 3.52 (2.97–4.18) 3.49 (2.94–4.14)
Unknown 1.08 (1.04–1.12) 1.08 (1.05–1.12) 1.34 (1.18–1.52) 1.33 (1.18–1.52)
Gleason score
2–4 1.0 1.0 1.0 1.0
5–7 1.16 (1.11–1.21) 1.16 (1.12–1.21) 2.47 (2.01–3.05) 2.48 (2.01–3.05)
8–10 1.73 (1.66–1.82) 1.74 (1.66–1.82) 8.29 (6.73–10.21) 8.28 (6.72–10.20)
Unknown 1.36 (1.28–1.45) 1.36 (1.28–1.44) 3.69 (2.86–4.76) 3.70 (2.86–4.77)
Comorbidity score
0 1.0 1.0 1.0 1.0
1 1.61 (1.56–1.66) 1.60 (1.55–1.65) 1.03 (0.93–1.15) 1.03 (0.92–1.14)
2 2.26 (2.17–2.36) 2.23 (2.14–2.33) 1.18 (1.01–1.38) 1.16 (0.99–1.35)
 3 3.49 (3.33–3.66) 3.44 (3.28–3.60) 1.56 (1.30–1.87) 1.53 (1.27–1.84)
Composite SES (quartile from high to low)
1st — 1.0 — 1.0
2nd — 1.11 (1.07–1.16) — 1.25 (1.09–1.44)
3rd — 1.22 (1.17–1.27) — 1.22 (1.05–1.41)
4th — 1.31 (1.25–1.37) — 1.40 (1.20–1.64)
Missing — 1.19 (1.12–1.26) — 1.11 (0.88–1.40)
SES: socioeconomic status; 95% CI: 95% confidence interval; AJCC: American Joint Commission on Cancer.
a In models 1 and 3, the hazard ratio is adjusted for variables listed in the footnote of Table 4. Models 2 and 4 are adjusted for composite socioeconomic status in addition to above factors.
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insurance, the Healthy People 2010s goal40 of elim-
inating racial disparities in cancer survival is possi-
ble.
Our study found that Hispanics had a lower risk of
mortality from prostate carcinoma than did Cauca-
sians and African Americans, even though their socio-
economic status was similar to that of African Ameri-
cans. This mortality advantage among Hispanics has
often been described as the ‘Hispanic Paradox’ be-
cause their low socioeconomic status was a known
determinant of mortality as evidenced in our study,
and because they are also known to have a higher
prevalence of risk factors for mortality. Many studies
explored the reasons for this paradox, including the
‘healthy immigrant theory’ and the factor of strong
social support.41 However, a recent study reported
that the National Death Index may have underesti-
mated mortality for Hispanic men by 9%.41 The small
number of Hispanic subjects in our study may also
have generated some unstable results.
Our study has several strengths. First, it was a
population-based study, covering all incident cases of
prostate carcinoma in the 11 SEER regions. This large
cohort of patients were pathologically confirmed by
the SEER registries, one of the most authoritative data
sources on cancer. SEER registries also provided reli-
able information on tumor stage, grade, and long-
term followup on vital status.3–5,42 In addition, Medi-
care claims data enabled us to identify information on
patient comorbidity, which is a strong confounder of
survival. Furthermore, information on chemotherapy
and hormonal therapy can be uniquely identified from
Medicare claims data.43
This study also has several limitations. First, so-
cioeconomic variables are based on the zip code or
census tract level, and are imperfect proxy measures
of individual level socioeconomic status. Therefore, it
is possible that residual confounding was not properly
controlled in our analyses. One study using the Na-
tional Longitudinal Mortality Study data showed that
family income and education at the individual level
did not account for much of the excess risk for African
American men with prostate carcinoma compared
with Caucasian men.20
Second, we did not have information on physician
and hospital characteristics, which have also been
shown to be associated with cancer outcomes.24 We
also do not have information on patient or physician
preferences toward treatment such as choice of pros-
tatectomy. The marginal differences in survival be-
tween racial/ethnic groups after adjusting for educa-
tion were likely because of unmeasured factors such
as physician characteristics. Third, we only studied
Medicare beneficiary men age 65. The results for the
association between race/ethnicity and survival may
not be generalizable to younger patients. However,
most incident cases of prostate carcinoma occur in
older persons,1–5 so the findings will still be general-
izable to a large population. Furthermore, older
persons are often reported to be at higher risk of
underutilization of cancer therapies and are
underrepresented in clinical trials.44 Therefore, target-
ing this population would have great importance for
much-needed research in identifying health problems
and for improving quality of life. In addition, we ex-
amined only patients who had both Medicare Parts A
and B, and were not members of an HMO. The pat-
terns in survival may be different from other cases
excluded.
In conclusion, lower socioeconomic status was
strongly associated with decreased survival in men
with local/regional stage prostate carcinoma. The ra-
cial/ethnic disparities in survival in these men were
largely explained by socioeconomic status and other
factors. These findings have important public health
FIGURE 1. Kaplan–Meier survival curve by race/ethnic group (upper curve:
all-cause; bottom curve: prostate carcinoma-specific).
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implications if we are to achieve the goals of Healthy
People 2010, one of which is to eliminate health dis-
parities among different segments of the population.
Furthermore studies may be needed to address
whether this association is true in younger men with
prostate carcinoma and in subjects diagnosed with
prostate carcinoma in other parts of the world.
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